The logic of therapeutic vaccination differs fundamentally from preventive immunization. Rather than blocking infection, these vaccines are designed to treat existing cancers by activating tumor-specific immunity and strengthening immune surveillance. Yet the review is candid about the field’s central frustration: even though endogenous T-cell responses against tumors exist in most patients, they typically fail to control disease, and immune checkpoint blockade (ICB) therapy—drugs that release the molecular brakes on T cells—often cannot rescue those responses on its own. Vaccines are meant to supply what the tumor microenvironment suppresses: a large, specific, and activated pool of anti-tumor T cells. Combining vaccines with checkpoint inhibitors has produced encouraging outcomes, including improved survival and tumor reduction across multiple cancer types, but low immunogenicity and tumor heterogeneity remain stubborn obstacles.

Nucleic acid vaccines are the fastest-moving segment of the field. DNA vaccines deliver bacterial plasmids encoding tumor-associated antigens (TAAs) or neoantigens into the cell nucleus, where they are transcribed into mRNA and translated into target proteins. They are stable, cheap to manufacture, easy to store, and can encode multiple antigens to hedge against tumor heterogeneity. The trade-offs are significant: DNA must cross the nuclear envelope, an extra step that lowers antigen production efficiency, and theoretical genomic integration remains a safety consideration unique to DNA. Because their intrinsic immunogenicity is low, DNA vaccines generally require adjuvants, electroporation, or nanoparticle delivery, and few clinical successes have been reported. One notable exception is GNOS-PV02, a DNA plasmid encoding up to 40 personalized neoantigens, which is being tested with an IL-12-encoding plasmid and the PD-1 antibody pembrolizumab in a phase 1/2 trial in hepatocellular carcinoma with promising early results.

mRNA vaccines have captured most of the attention, and the review argues the hype is at least partly earned. mRNA only needs to reach the cytoplasm to begin producing antigen, avoiding the nuclear barrier, and it cannot integrate into the genome. Advances in lipid nanoparticle (LNP) delivery have dramatically improved mRNA stability and cellular uptake, while self-amplifying mRNA (samRNA) promises prolonged antigen expression at lower doses, though cancer applications remain at an early preclinical and clinical stage. A double-edged sword is innate immune sensing: mRNA triggers pattern recognition receptors such as RIG-I and Toll-like receptors, which can act as a built-in adjuvant but can also induce type-I interferon responses that inhibit translation of the vaccine itself. The flagship candidate is mRNA-4157, which encodes up to 35 neoantigen epitopes and is delivered in LNPs. Combined with pembrolizumab, it improved recurrence-free survival versus pembrolizumab alone in a phase 2 trial of patients with completely resected, high-risk cutaneous melanoma, and phase 3 trials are now underway in melanoma, non-small cell lung cancer, and cutaneous squamous cell carcinoma.

Peptide vaccines take a more direct approach, administering synthetic polypeptides that mimic TAAs or neoantigens, which are captured by antigen-presenting cells and used to prime CD8-positive and CD4-positive T cells. Their Achilles’ heel is size: short peptides can load directly onto MHC molecules on any cell, including non-professional antigen-presenting cells that induce tolerance rather than immunity. Synthetic long peptides containing both MHC class I and class II epitopes avoid this trap and reliably induce both T-cell compartments. To overcome weak immunogenicity, researchers pair peptides with Toll-like receptor agonists, checkpoint inhibitors, or nanoparticle carriers such as virus-like particles and liposomes. Clinical results are accumulating: EVX-01, a personalized vaccine of up to 15 neoantigen epitopes with the CAF09b adjuvant, is in phase 1/2 testing alongside checkpoint inhibitors, and SurVaxM, targeting survivin in newly diagnosed glioblastoma, significantly prolonged patient survival in a phase 2 trial combined with pembrolizumab. A new phase 1 trial is evaluating a nine-peptide vaccine with the TLR1/2 ligand XS15 in acute myeloid leukemia patients in first remission.

Cell-based vaccines exploit whole cells rather than defined antigens. Dendritic cell (DC) vaccines harvest a patient’s own antigen-presenting cells, load them ex vivo with tumor lysates, peptides, or antigen-encoding RNA, and reinfuse them to activate cytotoxic T cells. Whole tumor cell vaccines, using irradiated or genetically modified tumor cells, present a broad antigen repertoire that hedges against heterogeneity, and are often supercharged with adjuvants such as GM-CSF. The category’s proof of principle is Provenge (sipuleucel-T), the FDA-approved autologous DC vaccine for prostate cancer. GVAX, an irradiated GM-CSF-secreting tumor cell vaccine, improved disease-free and overall survival in pancreatic cancer patients when combined with the antibodies urelumab and nivolumab in a phase 2 trial. Ongoing phase 2 studies are testing the neoantigen-loaded DC vaccine NeoDC-Vac after chemoradiotherapy in locally advanced esophageal squamous cell carcinoma, and an autologous tumor lysate-loaded cDC1 vaccine in ovarian cancer. The review notes that high production costs, labor-intensive manufacturing, and variable patient responses still constrain this platform.

Virus-based strategies come in two flavors. Oncolytic viruses preferentially infect and replicate inside tumor cells, exploiting abnormal surface receptor expression and the weakened antiviral signaling—blunted interferon and PKR pathways—characteristic of cancer. As infected cells lyse, they release reactive oxygen species, cytokines, and damage-associated molecular patterns that ignite both innate and adaptive immunity, and epitope spreading helps the immune system recognize tumor antigens beyond those the virus carries. The landmark agent is T-VEC, the first FDA-approved oncolytic therapy: an attenuated herpes simplex virus deleted for ICP34.5 to enhance tumor-selective replication and reduce neurovirulence, and engineered to carry the GM-CSF gene to recruit dendritic cells and macrophages into the tumor. Viral vector vaccines, by contrast, use engineered adenoviruses, lentiviruses, or vaccinia viruses to deliver antigen genes into host cells, mimicking natural infection so effectively that adjuvants are often unnecessary. Their vulnerability is pre-existing vector immunity, which can neutralize the vaccine—a problem managed by heterologous prime-boost strategies that switch vectors between doses.

Two technological currents are reshaping the entire field. The first is artificial intelligence: machine learning tools such as NetMHC and DeepHLA mine genomic and transcriptomic data to predict which tumor mutations will yield immunogenic neoantigens that bind a patient’s HLA molecules, bypassing central immune tolerance and reducing off-target risk. GNOS-PV02 already uses such algorithms to select neoantigens by predicted binding affinity. But the review cautions that limited training datasets and ethnic bias in HLA haplotype data can undermine the generalizability of predictions. The second is delivery engineering: LNP surface charge can be tuned to redirect biodistribution to different organs, cholesterol analogues such as C-24 alkyl phytosterols enhance in vivo mRNA delivery, hydrogels act as depots for sustained antigen release—with one study finding that D- versus L-glutamate chirality in polypeptide hydrogels profoundly altered immune cell infiltration and T-cell exhaustion—and lentiviral particles pseudotyped with Sindbis virus glycoprotein can target mRNA directly to dendritic cells, boosting both humoral and T-cell responses.

The review’s most sobering conclusion is that no vaccine platform, however elegant, is likely to deliver durable clinical benefit alone. Combination is the operative word: pairing vaccines with anti-PD-1 and anti-CTLA-4 antibodies, cytokines such as IL-2 and IL-15 superagonist ALT-803, adoptive cell transfers like tumor-infiltrating lymphocyte therapy, or even radiotherapy and chemotherapy that can convert immunologically cold tumors into inflamed ones by breaking down physical barriers of tumor-associated fibroblasts and poor vascularization. Underlying biology still constrains outcomes: HLA diversity between patients complicates neoantigen prediction and blocks some patients from accessing promising TAA epitopes, while individual T-cell receptor repertoires and pMHC densities produce highly variable T-cell avidity—and recent work suggests low-avidity T cells actually drive endogenous tumor immunity. Toxicity, patient variability, and treatment resistance complicate combination regimens. Still, with 15,000 accesses and growing citations since its May 2025 publication, the review captures a field at an inflection point: after decades of disappointment, therapeutic cancer vaccines—personalized, AI-designed, and rationally combined—are finally delivering on their immunological promise.

Subject of Research: Therapeutic cancer vaccine platforms and their combination with immunotherapy

Article Title: Therapeutic vaccine strategies in cancer: advances, challenges, and future directions

Article References: Therapeutic vaccine strategies in cancer: advances, challenges, and future directions. (n.d.). https://doi.org/10.1007/s44272-025-00039-x

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00039-x

Keywords: therapeutic cancer vaccines, cancer immunotherapy, mRNA vaccines, DNA vaccines, neoantigens, peptide vaccines, dendritic cell vaccines, oncolytic viruses, viral vectors, immune checkpoint inhibitors, lipid nanoparticles, artificial intelligence

The Ludwig Laboratory for Cell Therapy will find its home within the prestigious Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. This integration will catalyze the extension of Dr. Coukos’s groundbreaking work, characterized by a bench-to-bedside research paradigm that seamlessly links laboratory discoveries with clinical applications. His prior work notably included orchestrating programs for the development, manufacture, and meticulous clinical evaluation of next-generation cellular immunotherapies and therapeutic cancer vaccines. This effort embodies a sophisticated bidirectional translation between foundational immunobiology and patient-centered trials, emphasizing the optimization of T cell-mediated therapies.

Within Weill Cornell’s academic framework, Dr. Coukos holds a full professorship in immunology in medicine, supplemented by a secondary appointment in the Department of Pathology and Laboratory Medicine. His multifaceted role extends beyond laboratory leadership, as he also assumes the mantle of associate director for cell therapy at the Meyer Cancer Center. In this capacity, he will lead a highly interdisciplinary team tasked with the ambitious objective of engineering next-generation T cell therapies. These therapies will be rigorously subjected to clinical translational analyses to deepen understanding of their mechanistic vulnerabilities and therapeutic potential.

The significance of Dr. Coukos’s recruitment is underscored by Dr. Jedd Wolchok, director of the Meyer Cancer Center, who emphasizes Dr. Coukos’s preeminence in the realm of cellular immunotherapies. According to Dr. Wolchok, this move thrusts Weill Cornell into an elite echelon of institutions equipped for cutting-edge cell therapy research. This confluence of expertise is expected to accelerate advancements in harnessing T cells to combat a spectrum of malignancies, marking a watershed moment in the evolution of immune-oncology.

Dr. Massimo Loda, chair of the Department of Pathology and Laboratory Medicine, highlights Dr. Coukos’s exemplary status as a tumor immunology pioneer. His intellectual acumen, especially in elucidating the immune system’s capacity to target malignancies like melanoma and ovarian cancer, has spawned meaningful clinical advances. Dr. Loda notes that Dr. Coukos’s comprehensive scientific insight will be instrumental in broadening the horizons of cellular immunotherapy to encompass diverse tumor histologies currently underserved by existing regimens.

In addition to his responsibilities at the Meyer Cancer Center, Dr. Coukos holds the position of associate director for precision cell immunotherapy at the Englander Institute for Precision Medicine. This role focuses on leveraging sophisticated systems biology approaches to decode the complex molecular and cellular networks driving tumorigenesis. His work aims to translate this knowledge into the rational design of highly individualized cellular immunotherapies, with a pronounced emphasis on refined T cell-based interventions. This personalized approach dovetails with emergent paradigms in precision oncology, where treatment regimens are tailored to the patient’s unique tumor microenvironment and immune landscape.

Dr. Olivier Elemento, director of the Englander Institute, accentuates the synergies anticipated from Dr. Coukos’s arrival. By harnessing the institute’s advanced platforms—such as tumor-derived organoids, comprehensive systems biology analytics, and artificial intelligence-based predictive modeling—Dr. Coukos will spearhead the refinement and optimization of cellular immunotherapies. These technologies enable high-fidelity modeling of tumor-immune interactions and empower the development of bespoke cell therapies capable of surmounting immune evasion and enhancing therapeutic efficacy.

Dr. Coukos’s academic and clinical pedigree is distinguished by rigorous training and international experience. He earned his medical degree in 1987 from the University of Modena School of Medicine in Italy, followed by a doctorate in reproductive biology in 1990 from the University of Patras School of Medicine in Greece. His early clinical foundation was shaped through a residency in obstetrics and gynecology at the University of Modena’s hospital, after which he transitioned to the United States. At the University of Pennsylvania Medical Center, he completed postdoctoral research fellowships in reproductive cell biology and oncolytic viral-gene therapy, alongside a second residency training in obstetrics and gynecology, further diversifying his expertise.

Beginning his faculty career in 2000 at the University of Pennsylvania, Dr. Coukos rose through academic ranks from assistant professor to holder of the Celso Ramon Garcia Professorship by 2012. Subsequently, he accepted a full professorship at the University of Lausanne in Switzerland, where he also began his association with Ludwig Cancer Research as a full member in 2015. His leadership at the Ludwig Lausanne Branch catalyzed a vibrant research ecosystem focused on cellular immunotherapeutics, setting the stage for his current leadership role at Weill Cornell.

Dr. Coukos’s translational research program exemplifies a meticulous integration of tumor immunology, cell development biology, and clinical oncology. His work meticulously investigates T cell differentiation, activation, and trafficking within the tumor microenvironment, designing innovative strategies to overcome immunosuppression and resistance mechanisms. He has been at the forefront of developing not only adoptive T cell therapies but also personalized cancer vaccines that prime endogenous immune responses.

The integration of Dr. Coukos’s laboratory within Weill Cornell and its collaborative units promises to leverage cutting-edge technologies, from single-cell transcriptomics to engineered cellular constructs and CRISPR-mediated genome editing. These technological advances will underpin the development of robust, highly specific, and durable cell-based therapies, advancing the field closer to achieving curative outcomes for malignancies long considered refractory to immunotherapy.

Ultimately, Dr. Coukos’s arrival represents a critical step towards realizing the potential of precision immunotherapy as a cornerstone of contemporary oncology. His multidisciplinary approach—spanning molecular immunology, clinical investigation, and systems biology—offers a transformative framework for the next era of cancer treatment, embodying the promise of tailoring immune-based interventions that are as sophisticated and adaptive as the diseases they aim to conquer.

Subject of Research: Tumor immunology, cellular immunotherapy, T cell therapies, cancer vaccines, precision cell immunotherapy.

Article Title: Dr. George Coukos to Lead Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine

News Publication Date: Not specified

Web References: Ludwig Cancer Research announcement (specific URL not provided)

Keywords: Cell therapies, T cell development, Immunotherapy